Proposed $1.0 million Convertible Debenture and concurrent $600,000 Private Placement Intended to Support Near-Term Operations Board and Management Enhancements Strengthen Governance and Capital Markets ExecutionCurrent Convertible Debenture Maturity Extended; Further...
DOWNLOAD Vancouver, British Columbia, January 8, 2026 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery and Variational AI, a leader in...
Be in the know with the Rakovina Therapeutics monthly investor newsletter! Each month you’ll find out what’s going on with the company and be the first to receive news release straight to your inbox.
Recent Comments